Objective: Inhibins and activins are members of the transforming growth factor b superfamily and are known to modulate the growth and differentiation of several cell types. The present study investigated the localization of inhibin and activin subunits in human normal and pathological breast tissues. Design: A cross-sectional study comparing the expression of inhibin/activin subunits a, bA and bB in surgical specimens from women undergoing reductive mammoplasty (classified, according to the phase of the menstrual cycle, as follicular, luteal, or postmenopausal), and patients submitted to lumpectomy for fibrocystic disease, benign (intraductal papilloma, adenomyoepithelioma, and hamartoma) or malignant breast neoplams (intraductal, intralobular, and invasive carcinoma). Methods: Immunohistochemistry was used to localize inhibin a and activin bA and bB subunits in the cytoplasm of epithelial cells of mammary glands. Dimeric activin A, inhibin A and inhibin B were measured by specific two-site enzyme immunoassay in the cystic fluid collected from patients with fibrocystic disease. Results: An intense staining for the a inhibin subunit and a mild staining for bA and bB subunits were present in samples obtained from normal breast tissue regardless of menstrual cycle phase, and in fibrocystic disease and benign neoplasms. Carcinoma cells stained weakly to moderately for a subunit and were negative for bA and bB subunits. Fibrocystic disease was associated with absence of bA subunit expression in normal epithelial cells and intense staining for all subunits in the apocrine cells. Immunoreactive inhibin A, inhibin B, and activin A were also present in cystic fluid, suggesting a local secretion of these proteins. Conclusion: These data suggest a local expression and secretion of inhibin and activin in human normal, fibrocystic disease and neoplastic breast tissues. The low expression of these proteins may facilitate abnormal cell proliferation in breast carcinoma.
Introduction
Inhibins and activins are dimeric proteins that share a considerable sequence homology with the transforming growth factor-b family (1) . Inhibin is a 32 kDa heterodimer composed of an a subunit and one of two b subunits, named bA and bB, which characterize inhibin A and B respectively. The dimerization of two inhibin b subunits gives rise to activin A (bA-bA), activin B (bB-bB) or activin AB (bA-bB).
Inhibin was initially isolated from the gonads and identified as modulator of the release of follicle-stimulating hormone from the anterior pituitary gland (1) . Recent studies indicated that inhibin and activin are expressed in a wide variety of tissues and have a critical role in growth and developmental mechanisms, modulating the proliferation and differentiation of several cell types (2, 3) . The expression and secretion of inhibin and related proteins in various tumours is currently under investigation (4) (5) (6) (7) (8) (9) (10) . The tumoral secretion of inhibin and activin into systemic circulation is suggested by the high serum levels of immunoreactive inhibin in women with ovarian or placental carcinoma (4, 5) , and by the high levels of serum activin A associated with solid tumours (9, 10) .
Inhibins and activins seem to participate in the differentiation of mammary epithelial cells (11) and in the growth and morphogenesis of primary or transformed mammary epithelial cells (12, 13) . In spite of the putative relevance of inhibin-related proteins to the control of breast cancer development, the local expression of these proteins in breast lesions is still unknown.
In order to find out whether mammary epithelial cells express these proteins in normal and in pathological conditions, we investigated the localization of immunoreactive inhibin and activin subunits in histological specimens of healthy breast tissue, benign lesions and breast cancer. An additional objective of this study was to verify whether dimeric inhibin A, inhibin B and activin A are secreted into the cystic fluid of benign adenomatous cysts.
Materials and methods

Patients
Informed consent was obtained from all participants and the study was approved by the institutional Human Investigation Committee. A sample of women (n = 31) submitted to reduction mammoplasty (n = 14) or surgical lumpectomy for symptomatic lesions (n = 17) was studied. The patients who underwent reduction mammoplasty were divided into three groups according to the stage of their menstrual cycle: 1) women in the follicular phase (n = 5, age range 21-47 years); 2) women in the luteal phase (n = 5 patients, age range 23-41 years); and 3) women in postmenopause (n = 4, age range 59-64 years). All patients enrolled in the first two groups had regular menstrual cycles and the cycle phase was determined by the last menstrual period.
The surgically resected lesions of the 17 patients in this group (age range 30-58 years) were diagnosed as follows: a) fibrocystic disease (n = 5); b) benign tumours (n=5) comprising intraductal papilloma (n = 3), adenomyoepithelioma (n = 1), and breast hamartoma (n = 1); c) breast carcinoma (n = 7) including intraductal carcinoma (n = 2), intralobular carcinoma (n = 1), invasive ductal carcinoma (n = 3), and invasive tubulolobular carcinoma (n = 1).
Cystic fluid samples were collected by needle aspiration from patients with fibrocystic disease (n = 5, age range 42-51 years) and stored at -20 ЊC until assayed for activin A, inhibin A and inhibin B concentrations.
Tissue collection and immunohistochemistry
The tissue samples were fixed in 10% buffered formalin, embedded in paraffin and processed routinely. To improve antigen retrieval, paraffin sections were rehydrated and heated in a microwave oven (800 W for 5 min and 300 W for 10 min) using 0.01 mol/l citrate buffer, pH 7.3. All sections were stained by the peroxidase-streptavidin-biotin technique. Briefly, after blockade of endogenous peroxidase, the sections were incubated overnight with the primary antibody, followed by biotinylated link antibodies and peroxidase streptavidin (LSABTM, Dako, Glostrup, Denmark) for 30 min each. After the development of peroxidase with diaminobenzidine, the slides were counterstained in Mayer's haematoxylin, dehydrated and mounted in Eukitt.
The following highly specific antisera were used: rabbit anti-a (1-26)-Gly-Tyr diluted 1:100, mouse antibA (81-113)-NH 2 , and mouse anti-bB (81-112)-NH 2 diluted 1:25. These were affinity purified polyclonal antisera raised against synthetic peptide fragments and kindly donated by Dr W Vale (Salk Institute, San Diego, USA). Their characteristics have previously been described in detail (14) and no cross-reaction between the three antisera has been observed.
Positive controls were carried out using standard positive placental sections stained with the specific antibodies. Negative controls consisted of breast tissue sections in which the primary antibody was replaced by non-immune rabbit or mouse serum. The immunostaining was evaluated by estimating the distribution and the intensity of positive cells. A positive reaction was characterized by the presence of granular brown staining in the cytoplasm. Intensity of staining was graded semiquantitatively on a scale of 0-3 arbitrary units, with 0 indicating no detectable staining, 1 = weak, 2 = moderate, and 3 = strong immunostaining.
Inhibin A, inhibin B, and activin A assays
Inhibin A, inhibin B and activin A concentrations in breast cystic fluid were measured, as previously described (9), by specific two-site enzyme immunoassays purchased from Serotec (Oxford, UK). The inhibin A detection limit was 20 pg/ml serum, with intra-and interassay coefficients of variations (CV) for quality control samples less than 4.0% and 8.0% respectively. The assay limit of detection for inhibin B was less than 30 pg/ml in serum and less than 15 pg/ml in cystic fluid. Within-and between-plate CVs in this case were less than 5.0% and 9.0% respectively. The limit of detection for activin A was less than 100 pg/ml, and intra-and interassay CVs were 5.0% and 9.0%, respectively. Cross-reactions for each assay with the various inhibin-related proteins were less than 0.5%.
Statistical analysis
The concentrations of dimeric activin and inhibin in cystic fluid are reported as means Ϯ standard deviations (S.D.). The intensity of immunostaining for inhibin/activin subunits is expressed as medians and ranges, and differences between groups were assessed by Kruskal-Wallis analysis of variance followed by Dunn's test for non-parametric multiple comparisons.
Results
In normal breast tissue, ductal and lobular epithelial cells were strongly immunoreactive for a antiserum and weakly positive for bA and bB antibodies (Fig. 1) . No immunoreactivity was seen in the myoepithelial cells, contrasting with the strong a subunit immunostaining observed in the endothelial cells. No difference between the phases of the menstrual cycle was found; however, there was a moderate decrease of intensity of staining for a subunit in menopausal women (P < 0.05, Fig. 2 ). Negative controls failed to show any immunostaining for the three antigens tested.
In the benign neoplasms, epithelial cells were moderately or strongly positive for a subunit antiserum and weakly stained for bB and bA subunits. Apocrine epithelial cells in the fibrocystic disease showed an intense immunostaining for all antigens (Fig. 1), whereas normal epithelial cells around the cysts were faintly stained for bB and negative for bA subunit. In the malignant lesions, the epithelial neoplastic cells expressed a weak to moderate positivity for a subunit antiserum, but were negative for bA and bB subunits, contrasting with the pattern observed in normal breast tissue (P < 0.05, Fig. 2 ). Endothelial cells were positive only for a subunit antiserum.
As shown in Fig. 3 , measurable concentrations of dimeric activin A, inhibin A and inhibin B were found in cystic fluid samples from patients with fibrocystic disease. The concentrations of activin A (150 Ϯ 40 pg/ml) were greater than those of inhibin A (114 Ϯ 17 pg/ml) and inhibin B (35 Ϯ 15 pg/ml).
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Figure 1
Representative examples of mammary tissue immunostained for inhibin/activin subunits a (left: a, d, g, j), bA (centre: b, e, h, k), and bB (right: c, f, i, l). Breast tissue samples were obtained from surgical resection of normal mammary tissue (a-c), fibrocystic disease (d-f), benign adenomyoepithelioma (g-i), and intraductal carcinoma (j-l). Specific immunostaining is indicated by the presence of granular brown staining in the cytoplasm. Original magnifications were × 400 (a-f) and × 250 (g-l).
Discussion
This is the first demonstration that inhibin and activin a and b subunits are expressed in human breast tissue. Normal breast tissue expressed inhibin/activin a, bA and bB subunits without showing variation during the menstrual cycle, with a slight reduction of a subunit signal in samples from postmenopausal women. Conversely, neoplastic epithelial cells lacked bA and bB expression while showing a low level of staining for immunoreactive a subunit. These findings suggest that ductal and lobular epithelial cells normally produce inhibin-related peptides, possibly under regulatory mechanisms independent of menstrual-cycle-related changes in circulating sex hormones. Moreover, the present data indicate that the synthesis of inhibin/ activin subunits is modified in cells from invasive breast carcinoma.
The localization of immunoreactive inhibin/activin subunits in breast tissue suggests a local synthesis by mammary epithelial and endothelial cells, even though the immunohistochemical localization does not exclude the possibility that cells have captured the proteins from outside sources. Parallel identification of their respective messenger ribonucleic acid sequences is still required to confirm that inhibin/activin subunits are actually produced by breast cells in vivo. However, our data provide indirect evidence supporting a local production of activin and inhibin in the breast. The lack of differences during the menstrual cycle is in contrast with the cyclic changes that characterize serum inhibin concentrations (15) . The presence of activin and inhibin dimers in cystic fluid more likely reflects local production and secretion, rather than a mere transudation from serum, because the circulating concentrations of activin A in fertile women are substantially lower than those of inhibin A and inhibin B (16), contrasting with the relatively higher activin A concentration found in cystic fluid. Furthermore, mRNA sequences encoding bA subunit and activin RII receptor have been identified in selected populations of normal cultured human breast cells (12) .
The physiological role of these peptides in the breast remains unknown. Nevertheless, the significance of decreased a and b subunits in neoplastic cells is potentially relevant for tumour growth. The proliferation of breast cancer cell lines in vitro may be inhibited by activin A, and this mechanism is dependent on oestrogen receptor expression (17) . The antiproliferative effect of human chorionic gonadotrophin on immortalized human breast epithelial cells is accompanied by the immunocytochemical expression of inhibin/activin a and b subunits (18) .
In conclusion, the present data suggest a different expression of inhibin/activin subunits in normal mammary epithelium, fibrocystic disease, and benign and malignant breast tumours. The low expression of these proteins in carcinoma tissue may facilitate abnormal cell proliferation.
